Evidence map›Paper›PMID 41226376›Full record

ReviewInternational journal of molecular sciences2025

JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms.

Michela Perrone, Sara Sergio, Beatrice Pranzo, Amalia Tarantino, Giuseppina Loglisci, Rosella Matera, Davide Seripa, Michele Maffia, Nicola Di Renzo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michela PerroneLaboratory of Clinical Proteomic, "V. Fazzi" Hospital, 73100 Lecce, Italy.ORCID 0009-0001-5369-9877
Sara SergioLaboratory of Clinical Proteomic, "V. Fazzi" Hospital, 73100 Lecce, Italy.ORCID 0000-0002-4490-4189
Beatrice PranzoLaboratory of Clinical Proteomic, "V. Fazzi" Hospital, 73100 Lecce, Italy.ORCID 0009-0001-8887-5180
Amalia TarantinoHematology Laboratory, Hematology and Stem Cell Transplant Unit, "V. Fazzi" Hospital, 73100 Lecce, Italy.
Giuseppina LoglisciHematology and Stem Cell Transplant Unit, Onco-Hematological Department, "V. Fazzi" Hospital, 73100 Lecce, Italy.
Rosella MateraHematology Laboratory, Hematology and Stem Cell Transplant Unit, "V. Fazzi" Hospital, 73100 Lecce, Italy.
Davide SeripaHematology Laboratory, Hematology and Stem Cell Transplant Unit, "V. Fazzi" Hospital, 73100 Lecce, Italy.
Michele MaffiaLaboratory of Clinical Proteomic, "V. Fazzi" Hospital, 73100 Lecce, Italy.ORCID 0000-0003-0665-4534
Nicola Di RenzoHematology and Stem Cell Transplant Unit, Onco-Hematological Department, "V. Fazzi" Hospital, 73100 Lecce, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The JAK2 46/1 ("GGCC") haplotype is an inherited genetic variation within the

Indexed as

CarcinogenesisDrug Resistance, NeoplasmHaplotypesHematologic NeoplasmsJanus Kinase 2Myeloproliferative DisordersGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideJAK2 protein, humanJanus Kinase 2JAK2 haplotype GGCC_46/1JAK V617F mutationmyeloproliferativeneoplasmonco-drug resistancerisk stratification

Identifiers

PMID41226376
PMCPMC12609092

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.